Brief: Intercept Pharmaceuticals- On Jan 24, Co, Unit Entered Into Settlement Agreement With Amneal EU, Limited, Amneal Pharmaceuticals Of New York, Llc

Intercept Pharmaceuticals

25/01/2023 13:10

Jan 25 (Reuters) - Intercept Pharmaceuticals Inc
 ICPT.O :
    * INTERCEPT PHARMACEUTICALS- ON JAN 24, CO, UNIT ENTERED
INTO
SETTLEMENT AGREEMENT WITH AMNEAL EU, LIMITED, AMNEAL
PHARMACEUTICALS OF NEW YORK, LLC
    * INTERCEPT- AGREEMENT RESOLVING PATENT LITIGATION
CONCERNING
SUBMISSION BY AMNEAL OF ANDA SEEKING APPROVAL TO MARKET GENERIC
VERSION OF OCALIVA
    * INTERCEPT - GRANTED AMNEAL NON-EXCLUSIVE,
NON-SUBLICENSABLE,
NON-TRANSFERABLE, ROYALTY-FREE LICENSE TO COMMERCIALIZE GENERIC
VERSION OF OCALIVA IN U.S.
    * INTERCEPT - SIMILAR PATENT LITIGATION PREVIOUSLY DISCLOSED
BY CO
AGAINST OTHER ANDA FILERS SEEKING APPROVAL TO MARKET GENERIC
OCALIVA REMAINS PENDING
    * INTERCEPT - CO, AMNEAL WILL FILE SETTLEMENT AGREEMENT WITH
FTC
AND DEPARTMENT OF JUSTICE AND WILL TERMINATE THEIR PENDING
LITIGATION

Further company coverage:  ICPT.O 
 ((Reuters.Briefs@thomsonreuters.com;;))